In a perimenopausal woman with menorrhagia, which combined oral contraceptive (COC) and what dosage should be used?

Combined Oral Contraceptives for Perimenopausal Menorrhagia

For perimenopausal women with menorrhagia, start with a monophasic combined oral contraceptive containing 30-35 μg ethinyl estradiol combined with levonorgestrel or norgestimate, taken continuously or in extended cycles to minimize bleeding episodes 1.

Recommended Formulations and Dosing

First-Line COC Options:

• Ethinyl estradiol 30-35 μg + levonorgestrel (second-generation progestin)
• Ethinyl estradiol 30-35 μg + norgestimate (second-generation progestin)

These formulations are preferred because second-generation progestins carry lower thrombotic risk compared to third-generation progestins, cyproterone acetate, or drospirenone 2. This is particularly important in perimenopausal women who have age-related increased cardiovascular risk.

Dosing Strategy:

Use extended or continuous regimens rather than standard 21/7 cycling 1. This approach:

• Optimizes ovarian suppression and contraceptive effectiveness
• Minimizes hormone-free intervals that can trigger breakthrough bleeding
• Reduces menstrual blood loss more effectively
• Addresses the erratic bleeding patterns common in perimenopause

Alternative Formulations if Standard COCs Fail

If ethinyl estradiol-based COCs are contraindicated due to cardiovascular risk factors or cause unacceptable side effects, consider:

17β-estradiol-based combined oral contraceptives:

• 17β-estradiol + nomegestrol acetate (first choice)
• 17β-estradiol + dienogest (alternative)

These formulations avoid the "first-pass hepatic effect" and have a more favorable cardiovascular profile 3.

Important Clinical Considerations

Cardiovascular Risk Assessment:

Before prescribing any COC in perimenopause, screen for:

• Hypertension (contraindicated if ≥160/100 mmHg)
• Smoking status (not a contraindication under age 50, but increases thrombotic risk)
• Personal or family history of venous thromboembolism
• Migraine with aura (absolute contraindication)
• Diabetes with vascular complications

The thrombotic risk with COCs increases 4-fold overall but remains low at <0.5 per 1,000 woman-years 2. However, this baseline risk increases with age, making careful patient selection critical.

Efficacy for Menorrhagia:

Moderate-quality evidence shows COCs reduce heavy menstrual bleeding from baseline rates to achieve treatment success in 12-77% of women (compared to 3% with placebo) 4. The mechanism involves:

• Inducing regular shedding of thinner endometrium
• Inhibiting ovulation
• Stabilizing erratic perimenopausal hormonal fluctuations

When COCs Are Insufficient:

If menorrhagia persists despite COC use, the levonorgestrel intrauterine system (LNG-IUS) is more effective (OR 0.21,95% CI 0.09-0.48) 4. Consider switching to LNG-IUS if:

• Bleeding remains unacceptable after 3-6 months of COC use
• Patient develops contraindications to estrogen
• Patient prefers long-acting reversible contraception

Duration of Use:

Women can safely use COCs until age 50 if no contraindications develop 5, 6. After age 50, reassess annually for:

• Development of cardiovascular risk factors
• Need for continued contraception
• Transition to menopausal hormone therapy if appropriate

Practical Prescribing Algorithm

1. Screen for absolute contraindications (severe hypertension, thrombophilia, migraine with aura, active liver disease, cardiovascular disease)

2. If no contraindications exist:

   • Start monophasic COC with 30-35 μg ethinyl estradiol + levonorgestrel or norgestimate
   • Prescribe extended/continuous regimen (skip placebo weeks or use only 4 placebo days per cycle)

3. If cardiovascular risk factors present but not absolute contraindications:

   • Consider 17β-estradiol-based COC (nomegestrol acetate or dienogest)
   • OR switch to progestin-only methods

4. Reassess at 3 months:

   • If bleeding controlled and tolerated: continue
   • If persistent heavy bleeding: switch to LNG-IUS
   • If intolerable side effects: consider alternative formulation or non-hormonal options

Common Pitfall to Avoid:

Do not use standard 21/7 cycling in perimenopausal menorrhagia. The hormone-free interval allows endometrial buildup and breakthrough bleeding, defeating the therapeutic purpose. Extended or continuous regimens are essential for optimal bleeding control 1.